SCH 79797, a selective PAR1 antagonist, protects against ischemia/reperfusion-induced arrhythmias in the rat hearts

November 2016
European Review for Medical & Pharmacological Sciences;Nov2016, Vol. 20 Issue 22, p4796
Academic Journal
OBJECTIVE: Thrombin is implicated in the genesis of arrhythmias and activation of thrombin receptors exacerbated ventricular arrhythmias following coronary artery ligation. The present study was designed to investigate the possible protective effect of the protease- activated receptor-1 antagonist, SCH79797 against ischemia and reperfusion arrhythmias in the rat heart. MATERIALS AND METHODS: Healthy male Wistar rats (250-350 g) were anesthetized with urethane. Coronary artery ligation was performed for 5 minutes followed by 10 minutes reperfusion. Rhythm disturbances were monitored throughout the ischemia and reperfusion periods. Drugs injected were SCH79797 dihydrochloride (6.25, 12.5, 25 and 100 μg/kg), glibenclamide (5 mg/kg) and N-nitro L-arginine methyl-ester hydrochloride (25 mg/kg). The control group was injected with dimethylsulfoxide (0.1 ml). RESULTS: SCH79797 dihydrochloride reduced the number of premature contraction, prevalence and duration of ventricular tachycardia, prevalence and duration of ventricular fibrillation during both the ischemic and reperfusion periods in a dose-dependent manner. There is a trend for N-nitro L-arginine methylester hydrochloride to increase all parameters of arrhythmias in SCH79797 dihydrochloride (25 μg/kg) treated rats, but glibenclamide (5 mg/kg) significantly (p < 0.05) increased these parameters. CONCLUSIONS: SCH79797 dihydrochloride induced an antiarrhythmic effect in the anesthetized rat. This protective effect could possibly be mediated by activation of nitric oxide synthase and/or of ATP-sensitive potassium channels.


Related Articles

  • Data from TRACER Study of Vorapaxar, Merck's Investigational Medicine for Cardiovascular Disease, Presented at AHA and Published in NEJM.  // Biomedical Market Newsletter;11/14/2011, Vol. 21, p282 

    The article presents the results of the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) study led by North Carolina's Duke Clinical Research Institute (DCRI). The study is the first clinical trial of vorapaxar from Merck & Co. Inc. for the prevention...

  • A fingerprint pair analysis of hERG inhibition data. Springer, Clayton; Sokolnicki, Katherine L. // Chemistry Central Journal;2013, Vol. 7 Issue 1, p1 

    Background Drugs that bind to the human Ether-a-go-go Related Gene (hERG) potassium channel and block its ion conduction can lead to Torsade de Pointes (TdP), a fatal ventricular arrhythmia. Thus, compounds are screened for hERG inhibition in the drug development process; those found to be...

  • Effects of Ranolazine on Torsades de Pointes Tachycardias in a Healthy Isolated Rabbit Heart Model. Sossalla, Samuel; Wallisch, Nora; Toischer, Karl; Sohns, Christian; Vollmann, Dirk; Seegers, Joachim; Lüthje, Lars; Maier, Lars S.; Zabel, Markus // Cardiovascular Therapeutics;Aug2014, Vol. 32 Issue 4, p170 

    Purpose Torsades de pointes ( Td P) tachycardias are triggered, polymorphic ventricular arrhythmias arising from early afterdepolarizations ( EADs) and increased dispersion of repolarization. Ranolazine is a new agent which reduces pathologically elevated late INa but also IKr. Aim of this study...

  • The Expression of the Thrombin Receptors PAR-3 and PAR-4 is Downregulated in Pancreatic Cancer Cell Lines. Rudroff, Claudia; Richard, Annette; Hilswicht, Sarah; Neugebauer, Edmund A. M. // Jurnalul de Chirurgie;2014, Vol. 10 Issue 1, p31 

    Background: Patients with pancreatic cancer frequently suffer from thrombosis as a consequence of excess thrombin generation. In addition to its role in the plasmatic coagulation cascade, thrombin induces numerous cellular effects by activating a unique group of G-protein-coupled receptors on...

  • Intravenous nicorandil can reduce QT dispersion and prevent bradyarrhythmia during percutaneous transluminal coronary angioplasty of the right coronary artery. Ueda, Hiroyasu; Hayashi, Tomoshige; Tsumura, Kei; Yoshimaru, Kiyomichi; Nakayama, Yasunori; Yoshikawa, Junichi // Journal of Cardiovascular Pharmacology & Therapeutics;Sep2004, Vol. 9 Issue 3, p179 

    Background: Nicorandil, a potassium channel opener, is used for the treatment of angina pectoris and has a pharmacologic preconditioning effect. This study evaluated whether intravenous nicorandil reduces QT dispersion and prevents bradyarrhythmia during percutaneous transluminal...

  • Predictors and Outcomes of Prolonged Ventilation after Coronary Artery Bypass Graft Surgery. CHRISTIAN, KEVIN; ENGEL, AMY M.; SMITH, J. MICHAEL // American Surgeon;Jul2011, Vol. 77 Issue 7, p942 

    This study investigated and compared the risk factors and outcomes of patients undergoing coronary artery bypass graft surgery with and without the occurrence of prolonged mechanical ventilation. Data in a cardiac surgery database were examined retrospectively. Data selected included any...

  • Repair of anomalous origin of right coronary artery in an adult patient using coronary artery implantation technique. DEMİRTÜRK, Orhan Saim; TÜNEL, Hüseyin Ali; COŞKUN, İsa; GÜLCAN, Öner; ÜLGER, Mediha Hacer; TEKİN, Abdullah // Gulhane Medical Journal;eyl2015, Vol. 57 Issue 3, p306 

    Anomalous origin of coronary arteries is rarely seen. However when the coronary artery courses between the ascending aorta and the pulmonary artery leading to myocardial ischemia clinically fatal results may occur. The fact that they are usually symptom-free, and they may be missed when no...

  • Is coronary artery bypass grafting the treatment of choice for diabetic patients with multivessel disease? Brooks, Nicholas // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;1/1/2011, Vol. 342 Issue 7787, p26 

    In this article, the author argues in support of the coronary artery bypass grafting (CABG) as the treatment choice for diabetic patients with multivessel disease. The author claims that CABG offers more permanent relief for diabetics. He compares percutaneous coronary intervention (PCI) and...

  • Novel Two-Step Classifier for Torsades de Pointes Risk Stratification from Direct Features. Parikh, Jaimit; Gurev, Viatcheslav; Rice, John J. // Frontiers in Pharmacology;11/14/2017, p1 

    While pre-clinical Torsades de Pointes (TdP) risk classifiers had initially been based on drug-induced block of hERG potassium channels, it is now well established that improved risk prediction can be achieved by considering block of non-hERG ion channels. The current multi-channel TdP...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics